Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Japanese Encephalitis

Japanese Encephalitis

Part of Flavivirus Infections

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Japanese Encephalitis

38 trials tracked for Japanese Encephalitis: 30 in phase 3 or 4 and 5 with published results. The most-cited published study has 44 citations.

38Trials tracked
30Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 7 Phase 3 23 Phase 2 6 Other / NA 2
  1. Phase 4 A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 Completed · 44 cited
  2. Phase 4 Post-licensure Safety Study of IMOJEV® in Thailand Completed · 22 cited
  3. Phase 4 Long-term Immunogenicity After Receipt of JE Vaccine and Antibody Response and Safety to a Booster Dose Completed · 19 cited
  4. Phase 3 Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV Completed · 19 cited
  5. Phase 3 Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects Completed · 8 cited
  6. Phase 4 Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine Completed
Show 32 more trials
  1. Phase 4 Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age Completed
  2. Phase 4 Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine Completed
  3. Phase 4 Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine Completed
  4. Phase 3 Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers Completed
  5. Phase 3 Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea Completed
  6. Phase 3 Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling Completed
  7. Phase 3 Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 Completed
  8. Phase 3 Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 Completed
  9. Phase 3 Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Completed
  10. Phase 3 Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study Completed
  11. Phase 3 Comparison of Three Batches of the Japanese Encephalitis Vaccine IC51 Completed
  12. Phase 3 Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 Completed
  13. Phase 3 Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. Completed
  14. Phase 3 Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers Completed
  15. Phase 3 A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX Completed
  16. Phase 3 Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country Completed
  17. Phase 3 Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 Completed
  18. Phase 3 A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers Completed
  19. Phase 3 Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects Completed
  20. Phase 3 Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines Completed
  21. Phase 3 Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 Completed
  22. Phase 3 Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers Completed
  23. Phase 3 A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults Completed
  24. Phase 3 Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51 Completed
  25. Phase 2 A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX Completed
  26. Phase 2 Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children Completed
  27. Phase 2 Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) Completed
  28. Phase 2 Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine Completed
  29. Phase 2 Safety and Efficacy Study of ChimeriVax™-JE and JE Inactivated Mouse Brain Vaccine in Children of Descending Age Completed
  30. Phase 2 A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults Completed
  31. N/A Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 Completed
  32. N/A Flavivirus Cross-priming Potential of IMOJEV Completed

Showing the 38 most-cited and recently-updated of 38 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Japanese Encephalitis: what the trials found

Multiple live attenuated Japanese encephalitis (JE) vaccines, including SA-14-14-2 and chimeric virus formulations like IMOJEV, CD-JEV, and JE-CV, demonstrate high seroprotection and seroconversion rates. Specifically, the SA-14-14-2 vaccine showed seropositivity rates of 98% to 100% for neutralizing antibodies 5 and demonstrated no interference with measles, mumps, or rubella immunity [4, 6]. IMOJEV achieved 97.4% to 100% seroconversion after a single primary dose 9 and maintained high seroprotection (100%) following a booster dose 10, while also showing 100% seroconversion in comparative studies 18.

Long-term immunogenicity is supported by several trials; for instance, the SA-14-14-2 vaccine showed robust seroprotection rates at three and four years post-initial vaccination 3. The IC51 vaccine demonstrated high neutralizing antibody titers (PRNT50 ≥ 1:10) at months 24 and 36 12, although some studies noted varying long-term immunogenicity metrics for specific formulations 21. Additionally, JE vaccines were shown to be effective when administered in combination with other vaccines, such as MMR or Rabies, without compromising the efficacy of those co-administered agents [16, 20].

For the clinician treating this condition

  • Live attenuated JE vaccines (e.g., SA-14-14-2 and IMOJEV) consistently achieve high seroprotection and seroconversion rates following both primary and booster doses.
  • JE vaccines can be administered concurrently with other vaccines, such as MMR or Rabies, without compromising the immunogenicity of the co-administered agents.
  • Long-term protection is evidenced by sustained neutralizing antibody titers several years post-vaccination for specific live attenuated formulations.

AI synthesis of 7 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Environmental and social factors influence arbovirus proliferation in changing climate conditions
Infectious Disease Cohort
Environmental and social factors influence arbovirus proliferation in changing climate conditions Rising Temperatures Push Dangerous Viruses Into New Communities
This review examines how environmental and social factors, including increasing temperatures and urbanization, affect the proliferation of a…
Warming weather pushes dangerous insect-borne viruses into new areas, making early warning systems and vaccines more critical than ever for …
Frontiers Apr 28, 2026
Japanese Encephalitis Vaccine Recommended as Key Prevention in Asia
Allergy & Immunology
Japanese Encephalitis Vaccine Recommended as Key Prevention in Asia Japanese encephalitis vaccine prevents most common cause of brain infection in Asia
A recommendation report identifies Japanese encephalitis virus as the most common vaccine-preventable cause of encephalitis in Asia.
Japanese encephalitis is the most common vaccine-preventable cause of brain infection in Asia, making vaccination a key protection for trave…
CDC Apr 4, 2026

Research across Flavivirus Infections

Related studies from across the Flavivirus Infections family.

ACIP issues recommendations for tick-borne encephalitis vaccine in U.S. travelers and lab workers
Allergy & Immunology
ACIP issues recommendations for tick-borne encephalitis vaccine in U.S. travelers and lab workers U.S. health advisors recommend tick-borne encephalitis vaccine for travelers and lab workers
The Advisory Committee on Immunization Practices has published recommendations for tick-borne encephalitis vaccine use among U.S.
U.S. health advisors now recommend the tick-borne encephalitis vaccine for travelers visiting endemic areas and lab workers handling the vir…
CDC Apr 4, 2026